Trial Profile
A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 06 Mar 2020 Status changed from completed to discontinued.
- 22 Feb 2019 Status changed from recruiting to completed.
- 29 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.